



Significance of TEAD Family in Diagnosis, Prognosis and Immune Response for Ovarian Serous Carcinoma

Xinxin Ren¹
Xiang Wang²
Bi Peng³
Qiuju Liang²
Yuan Cai³
Kewa Gao³
Yongbin Hu³
Zhijie Xu^{3,4}
Yuanliang Yan²

¹Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, People's Republic of China;

²Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, People's Republic of China;

³Department of Pathology, Xiangya Hospital, Central South University, Changsha, People's Republic of China;

⁴National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, People's Republic of China

Purpose: To explore the molecular profiles of transcriptional enhanced associate domain (*TEAD*) family in ovarian serous carcinoma (OSC).

Methods: In this study, we use bioinformatics methods including GEPIA, GE-mini, OncoPrint 3.0, Kaplan–Meier plotter, cBioPortal, WebGestalt, TIMER2.0 and DiseaseMeth2.0, and in vitro experimental RT-PCR to assess the expression profiles and prognostic significance of *TEAD* family in OSC.

Results: According to the bioinformatics analysis, *TEAD* family was abnormally expressed in OSC. In terms of prognosis, Kaplan–Meier plotter indicated that OSC patients with high level of *TEAD4* showed poor overall survival (OS), progression-free survival (PFS) and post progression survival (PPS). *TEAD* family also had significantly diagnostic values for OSC patients. Tumor Immune Estimation Resource (TIMER) algorithm indicated that *TEAD* family was significantly associated with different types of infiltrating immune cells, including B cells, macrophages, dendritic cells, neutrophils, CD8+ T cells and CD4+ T cells. Gene set enrichment analysis of *TEAD* family-associated coexpression genes was further explored. In in vitro experiments, the RT-PCR results showed the upregulated *TEAD2/4* in OSC tissues and cells (A2780 and TOV112D). Moreover, decreased expression of *TEAD2* could induce the ferroptosis through increasing the ROS accumulation.

Conclusion: Thus, *TEAD* family correlated with the diagnosis, prognosis and immune infiltration in OSC. These results could provide comprehensive understanding of *TEAD* family in the diagnosis and prognosis of OSC patients.

Keywords: *TEAD* family, Hippo pathway, ovarian serous carcinoma, expression profiles, prognosis, immune infiltration

Introduction

Ovarian cancer is the second cause of death from gynecologic cancers in the world.^{1,2} Despite great advances have been made in diagnosis and treatment, the 5-year relative survival rate of ovarian cancer is only 47%, even in the developed countries.³ Among all histological subtypes of ovarian cancer, the ovarian serous carcinoma (OSC) has the highest mortality rate.⁴ In addition, late-stage presentation has a 5-year relative survival rate of 29% compared to 92% for early-stage; however, 75% of the patients are diagnosed at the late-stage due to lacking effective diagnostic methods.⁵ Therefore, identifying novel biomarkers is essential for improving the diagnosis and prognosis of OSC patients.

Hippo signaling pathway, as an important signaling pathway for tumor progression, has the functions of regulating organ size and maintaining the dynamic balance

Correspondence: Yuanliang Yan
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China
Email yanyuanliang@csu.edu.cn

between cell proliferation and apoptosis.^{6,7} Transcriptional enhanced associate domain (*TEAD*) is a family of transcription factors that was initially screened by genetic mosaic in *Drosophila* because of its vital role in organ development.⁸ Studies have identified that there are currently four homologs of *TEAD* protein, TEAD1/2/3/4.⁹ As the downstream effectors of Hippo signaling pathway, *TEAD* proteins can regulate cell growth, proliferation and stem cell functions, which are closely related to the occurrence and development of cancer.¹⁰ Emerging reports have demonstrated that *TEAD* family plays a critical role in multiple types of cancer, including renal cancer, breast cancer and prostate cancer.^{11–13} However, the detailed mechanisms of *TEAD* family members in OSC need further confirmation.

The purpose of our study was to assess the biological significance of *TEAD* family members in OSC patients using comprehensive bioinformatics and experimental methods (Supplemental Table 1). *TEAD* family members have been discovered as the potential diagnostic and prognostic biomarkers for OSC patients for clinical practice.

Methods

Cell Culture

The human ovarian epithelial IOSE80 and the human ovarian cancer A2780, SKOV-3, OVCAR3 and TOV112D cell lines were obtained from the Cancer Research Institute, Central South University, China. The cells were maintained in Roswell Park Memorial Institute (RPMI)-DMEM medium (Gibco, Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Gibco) at 37°C and 5% CO₂.

Antibodies and Chemicals

The following antibodies were used in this study: TEAD2 (21159-1-AP, Proteintech), actin (66009-1-Ig, Proteintech). The ferroptosis inducer erastin (B1524), ferroptosis inhibitor ferrostatin-1 (A4371), apoptosis inhibitor ZVAD-FMK (A1902) and necroptosis inhibitor necrostatin-1 (A4213) were obtained from APEX BIO (Houston, USA).

RNA Extraction and Reverse Transcription PCR (RT-PCR)

The 20 formalin-fixed, paraffin-embedded (FFPE) specimens of OSC tissues and 8 normal ovary tissues were all obtained from the Department of Pathology, Xiangya Hospital. The ethics of our study was approved by the Ethics Committee of Xiangya Hospital of Central South University and the ethical approval number is 202110181. TRIzol (Invitrogen) was applied to extract total RNA. Then, 1 µg of RNA was reverse transcribed into cDNA by utilizing a PrimeScript™ RT kit (Takara, 6210) following the manufacturer's instructions. The SYBR Green kit and real-time fluorescent quantitative PCR (qPCR) system (Bio-Rad, USA) were applied for qPCR analysis, with 18S rRNA as the internal control. Finally, relative expression levels of target genes were decided using the 2- $\Delta\Delta$ CT method. The details of the *TEAD* family primer sequences used in the experiment were listed in Table 1.

Transfections

For siRNA transfection, cells were all transfected by using Lipofectamine 3000 reagent (L3000150, Invitrogen, USA) according to the manufacturer's protocol. The sense sequences of target gene siTEAD2 are listed below: siTEAD2-1-GAGTGAGCAGCCAGTATGA, siTEAD2-2-GGTTGCAGCTGGTAGAGTT.

Western Blot

Cells were lysed on ice with RIPA lysis buffer containing protease inhibitor for 15 min. After centrifugation at 13,500 × g for 15 min at 4 °C, the supernatants were collected and quantified using a BCA protein detection kit. Equal quantity of protein was resolved on SDS-PAGE. Then, PVDF membranes were blocked in 5% skim milk and incubated with different primary antibodies at 4°C overnight subsequently. After incubation with HRP-conjugated secondary antibody for 1h at room temperature, the signals were detected with a chemiluminescence reagent (Millipore, WBKLS0050).

Table 1 The *TEAD* Family Primer Sequences Used in RT-PCR

Primers	Forward Sequences	Reverse Sequences
TEAD1	ATGGAAGGATGAGTGA CTCTGC	TCCCACATGGTGGATAGATAGC
TEAD2	CTTCGTGGAACCGCCAGAT	GGAGGCCACCCTTTTCTCA
TEAD3	TCATCCTGTGACGACGAGGG	TCTTCCGAGCTAGAACCTGTATG
TEAD4	GAACGGGGACCCTCCAATG	GCGAGCATACTGTCTCAAC

Cell Viability Assay

Cells were plated into a 96-well plate (1000 cells/well) and cultured under the condition at 37°C with 5% CO₂. The next day, the old medium was discarded and the fresh medium containing 10% CCK-8 was added. The absorbance of each group was measured at 450nm.

ROS Assay

The reactive oxygen species (ROS) in cells were assessed using DCFDA/H2DCFDA - Cellular ROS Assay Kit (ab113851, Abcam) according to the manufacturer's instructions. Cells were stained by DCFDA Solution and incubated for 45 minutes at 37°C in the dark. Then, live cell microscopy was performed with filter set appropriate for fluorescein.

GEPIA

Gene Expression Profiling Interactive Analysis (GEPIA), a web-based tool to give rapid and customizable functionalities based on TCGA and GTEx data, could offer vital interactive and customizable functions including differential expression analysis, patient survival analysis, correlation analysis and so on.¹⁴ In the study, we used “single-gene analysis” in GEPIA to value the mRNA expression differences of *TEAD* family members in OSC tissues compared with normal tissues. Differences in mRNA expression were compared by Student's *t*-test, and $p < 0.05$ was considered statistical significance.

GE-mini

GE-mini is a movable visualization instrument that integrates gene expression data on the basis of TCGA and GTEx.¹⁵ The expression viewer could be used as a convenient method for showing expression profiles of tumor and tissue types. In the study, we used the tool to analyze the mRNA expression of *TEAD* family in OSC tissues. $P < 0.05$ was considered statistically significant.

Oncomine 3.0

Oncomine 3.0, containing 65 gene expression datasets composed of about 48 million gene expression surveys from more than 4700 microarray experiments, is a cancer microarray database and web-based data-mining platform with the purpose of contributing discovery from genome-wide expression analyses.¹⁶ In the study, we evaluate the *TEAD* family mRNA expression in OSC. $P < 0.05$ was considered to show a statistically significant difference.

Kaplan–Meier Plotter

Kaplan–Meier plotter is a database evaluating the relationship between gene expression and the prognostic value in cancer patients.¹⁷ In the study, we used the database to analyze the effect of expression of *TEAD* family on OSC patients' prognosis by means of overall survival (OS), progression-free survival (PFS) and post progression survival (PPS) curves. In addition, information was divided into high- and low-expression groups and HR and *p* values can be found on the figures. $P < 0.05$ was considered statistically significant.

cBioPortal

The cBioPortal for Cancer Genomics can be applied to analyze, visualize and download of large-scale cancer genomics and clinical data.¹⁸ In our study, we analyzed the genome map of the *TEAD* family in OSC tissues including mRNA expression and genetic alterations.

Protein–Protein Interaction

The STRING database is designed to gather and integrate functional interactions between the expressed proteins.¹⁹ In the study, we built the *TEAD*-associated protein–protein interaction (PPI) network using STRING.

WebGestalt

WebGestalt is a more extensive, mighty, flexible and visible gene set enrichment analysis toolkit.²⁰ Gene set enrichment analysis of *TEAD* family-associated coexpression genes was explored using WebGestalt algorithm, including gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG).

TIMER2.0

TIMER2.0 is used to analyze the immune infiltrates across diverse cancer types.²¹ Through the database, we obtained the relationship between *TEAD* family and six immune infiltrates (B cells, CD4+ cells, CD8+ cells, neutrophils, macrophages and dendritic cells).

Statistical Analyses

All experimental findings were shown as mean \pm standard deviation (SD). Student's *t*-test was used to explore the difference between two groups. $P < 0.05$ was considered statistically significant.

Results

Abnormal Expression of the *TEAD* Family in OSC Patients

Firstly, we used bioinformatics databases to evaluate the expression profiles of *TEAD* members in normal and OSC patients. Using GEPIA with the criterion of $|\text{Log}_2\text{FC}| > 2$ and $p < 0.05$, we found the decreased *TEAD1/3* and increased *TEAD2/4* in OSC tissues (Figure 1A). In addition, from GE-mini database, we discovered that *TEAD2/3/4* were upregulated; however, *TEAD1* was downregulated in OSC tissues compared to normal tissues (Figure 1B). The Lu Ovarian dataset obtained from Oncomine revealed the upregulated expression levels of *TEAD2/4* (Figure 1C). Then, RT-PCR was performed to confirm the upregulated *TEAD2/4* in OSC cells A2780 and TOV112D compared with the normal ovary cell IOSE80 (Figure 1D, Supplemental Table 3). Moreover, the transcriptional levels of *TEAD2/4* were significantly increased in OSC tissues compared to the normal ovary tissues (Figure 1E, Supplemental Table 4).

The Prognostic and Diagnostic Values of *TEAD* Family Members in OSC Patients

Kaplan–Meier Plotter was applied to evaluate the effects of *TEAD* family on patients' survival. In terms of OS, the high expression of *TEAD1/2/4* was associated with a shorter OS time (Figure 2A). Moreover, patients with higher transcription levels of *TEAD1/2/3/4* revealed shorter PFS (Figure 2B). Meanwhile, we assessed the prognostic value of the *TEAD* family on the PPS of OSC patients. Results displayed that the upregulation of *TEAD4* was significantly associated with a poor PPS, while upregulation of *TEAD1/2* was associated with good PPS (Figure 2C). In addition, the expression of *TEAD3* had no obvious association with the patients' OS and PPS (Figure 2A and C).

Subsequently, we analyzed the diagnostic values of *TEAD* family in OSC with ROC curves. From Xiantao Xueshu web tool (<https://www.xiantao.love/products>), we found that the area under the curve (AUC) of *TEAD1/2/3/4* was 0.690, 0.630, 0.673 and 0.958, respectively (Figure 3A–D). Thus, because of the highest AUC, *TEAD4* might have the potential to be as the diagnostic biomarker for OSC patients.

Genetic Alteration and Functional Enrichment Analysis of *TEAD* Family in OSC Patients

We developed an integrated biological function analysis to further investigate the molecular characteristics of *TEAD* family in OSC patients. From cBioPortal database, we obtained the genetic alterations information of the *TEAD* family members. Results showed that the alternation rates of *TEAD1/2/3/4* were 8%, 1.6%, 16% and 19% in the OSC samples, respectively (Figure 4A). Moreover, amplification and up-regulated expression were the main genetic alteration of *TEAD2/4* genes.

In addition, PPI analysis of *TEAD*-family-associated coexpressed genes was used to comprehend the biological functions of *TEAD* family in OSC patients. Firstly, we downloaded the 19,253 coexpressed genes related to *TEAD* family members in OSC patients through the cBioPortal database (Figure 4B). Then, using the criterion of $|\text{Spearman Correlation}| > 0.54$ and $p < 0.01$, we identified 200 coexpressed genes with *TEAD* family to conduct the PPI network (Supplemental Table 2). The PPI network revealed that ribosomal protein S27a (RPS27A), NHP2 and ribosomal protein S29 (RPS29) were the hub genes, which might regulate the biological functions of *TEAD* family in OSC (Figure 4B). Meanwhile, GO analysis indicated that the *TEAD* family was primarily gathered in biological regulation and metabolic processes in the biological processes. In aspect of cellular component and molecular function, *TEAD* family were mainly located in membrane and enriched in protein binding (Figure 4C). Furthermore, KEGG analyzed further verified that *TEAD* family was significantly connected with sensory perception and detection of chemical stimulus (Figure 4D).

Immune Cell Infiltration of *TEAD* Family in OSC Patients

The relationship between *TEAD* family and immune cell infiltration was analyzed by TIMER algorithm. The results revealed that there were negative associations between *TEAD1* expression and the infiltration of CD8+ T cells, CD4+ T cells, neutrophils and dendritic cells. The positive associations could be found between *TEAD1* expression and the infiltration of B cells and macrophages (Figure 5A). In addition, *TEAD2/3* were negatively related to B cells, CD8+ T cells, macrophages, neutrophils and dendritic cells, while positively correlated with CD4+




Figure 1 The expression of *TEAD* family in OSC. **(A–C)** The mRNA expression of *TEAD* family in OSC obtained from GEPIA, GE-mini and Oncomine databases. T and N represent the OSC tissues and normal tissues, respectively. **(D)** mRNA expression levels of different *TEAD* family members in normal ovary cell line IOSE80 and OSC cell lines A2780 and TOV112D experimented by RT-PCR. **(E)** The mRNA expression level of *TEAD* family members in the clinical samples. OSC represents ovarian serous carcinoma.




Figure 2 Analysis of *TEAD* family expression on the prognosis of OSC patients. (A–C) The relationship between *TEAD* family and OS, PFS and PPS in OSC patients described by Kaplan–Meier plotter, respectively.

T cells (Figure 5B and C). Interestingly, *TEAD4* was negatively relevant to all tumor-infiltrating immune cells, such as B cells, CD8+ T cells, CD4+ cells, macrophages, neutrophils and dendritic cells (Figure 5D). Furthermore, we used the Cox proportional hazard model to analyze the clinical significance of *TEAD* family and the infiltration of immune cells in OSC cancer. The results showed that CD4 + T cells, macrophages, neutrophils and *TEAD1*

expression were significantly correlated with the clinical outcome of OSC patients (Table 2).

TEAD2 Inhibited Ferroptosis in OSC

As we had known that the mRNA expression of *TEAD2* was obviously higher in OSC, then we discussed the protein level of *TEAD2* in OSC compared to normal ovary cells. Figure 6A has shown that the protein level




Figure 3 Evaluation of diagnostic value of *TEAD* family in OSC. (A–D) ROC curve analysis of *TEAD* family members for the diagnostic values of OSC patients.




Figure 4 Genetic alteration and functional enrichment analysis of *TEAD* Family in OSC patients. **(A)** Description of the mutation rates in each *TEAD* family member in OSC patients. **(B)** The PPI network of *TEAD* family-associated coexpression genes as completed by STRING and Cytoscape. **(C)** Bar plot of GO analysis in biological process, cellular component and molecular function. **(D)** KEGG enrichment analyzed by WebGestalt.

of *TEAD2* was significantly increased in OSC cell lines including A2780, TOV112D, SKOV-3 and OVCAR3 compared to normal ovary cell line IOSE80 (Supplemental Figure 1). Moreover, we explored the function of *TEAD2* in OSC by knocking down the *TEAD2* in A2780 cells (Figure 6B, Supplemental Figure 2). Through CCK8 test, we found that reduced the expression of *TEAD2* could promote the death of A2780 cells under the circumstance of erastin and the process could be reversed by ferrostatin-1; however, ZVAD-FMK and necrostatin-1 could not affect the death of A2780 cells (Figure 6C). Therefore, it was indicated that knocked down the *TEAD2* was able to accelerate the ferroptosis in OSC.

Furthermore, we discussed whether *TEAD2* could influence the ROS, which was the crucial indicator for ferroptosis. Results showed that knocked down *TEAD2* increased the ROS levels in A2780 cells after treating with erastin and ferrostatin-1 could reverse the process (Figure 6D and E). This suggested that *TEAD2* could suppress the ferroptosis by regulating the level of ROS in OSC.

Discussion

As the transcriptional partner of Yes-associated protein/transcriptional co-activator with PDZ-binding motif

(YAP/TAZ) in the Hippo signal pathway, *TEAD* family plays an important role in tumor progression.^{22,23} *TEAD1* could directly integrate with the hypoxia-inducible factor-1A (HIF-1A) promoter region and regulate the expression of HIF1A, facilitating the tumor glycolysis.^{24,25} *TEAD2* was significantly upregulated in hepatocellular carcinoma (HCC) and the higher expression was associated with poor OS time of HCC.^{26,27} In addition, *TEAD3* could promote the proliferation of gastric cancer cell line MKN-28 through increasing SLC35B4 expression.^{28,29} Abnormally expressed *TEAD4* could obviously cause epithelial-to-mesenchymal transition (EMT) in colon cancer.³⁰ However, the detailed roles of the *TEAD* family in OSC have not been explained. Our study was the first to explore the expression and function profiles of *TEAD* family in OSC. The results showed that *TEAD2/4* were significantly upregulated in OSC tissues and cells. In terms of the prognosis of OSC patients, the higher expression of *TEAD1/2/4* was significantly associated with poor OS and PFS. Upregulation of *TEAD4* was observably correlated with poor PPS in OSC; however, downregulation of *TEAD1/2* were related to poor PPS. In addition, the *TEAD* family presented frequent genetic alteration in OSC patients.




Figure 5 The associations between differentially expressed *TEAD* family members and immune cell infiltration. (A–D) The effect of *TEAD1/2/3/4* on the immune cell infiltration analyzed by TIMER2.0.

The interaction between immune infiltration cells and tumor cells had a significant influence on tumor development and progression.^{31–33} Based on the TIMER database, we found that the expression of *TEAD* family members was obviously associated with the immune infiltration cells. *TEAD2/3/4* were all significantly negative with *CD8+* T cells, macrophages, neutrophils and dendritic cells in OSC. *TEAD2* also had the inverse relationship

with B cells. These results indicated that *TEAD* family might be participated in the immune response. In addition, emerging studies have demonstrated the association of immune infiltration cells and prognosis in OSC patients.^{34–36} Similarly, in our study, several tumor-infiltrating immune cells, such as *CD4+* T cells, macrophages and neutrophils, were significantly correlated with the clinical outcome of OSC patients. Studies have shown

Table 2 The Cox Proportional Hazard Model of the *TEAD* Family and Six Tumor-Infiltrating Immune Cells in OSC

	Coef	HR	95% CI_l	95% CI_u	p-value	Sig
B_cell	-2.419	0.089	0.000	37.484	0.433	
CD8_T cell	-3.412	0.033	0.001	1.395	0.074	
CD4_T cell	-16.249	0.000	0.000	0.000	0.000	***
Macrophage	10.373	31975.540	138.446	7385075.059	0.000	***
Neutrophil	8.782	6518.659	1.207	35212863.516	0.045	*
Dendritic	-0.377	0.686	0.007	70.531	0.873	
TEAD1	0.349	1.418	1.140	1.764000e+00	0.002	**
TEAD2	-0.135	0.874	0.711	1.074	0.201	
TEAD3	-0.262	0.770	0.585	1.013	0.062	
TEAD4	0.223	1.250	0.951	1.643	0.110	

Notes: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure 6 TEAD2 inhibited ferroptosis in A2780 cells. **(A)** The expression of TEAD2 in normal ovary cell line IOSE80 and OSC cell lines A2780, TOV112D, SKOV-3 and OVCAR3. **(B)** Knock down of TEAD2 in A2780 cells. **(C)** Knockout of TEAD2 in A2780 cells facilitated the cell death induced by erastin in A2780 cells. A2780 cells deal with erastin (10 μM) with or without a cell death inhibitor including ferrostatin-1 (5 μM), ZVAD-FMK (10 μM) and necrostatin-1 (5 μM) for 24 h. Cell death was experimented by a CCK-8 kit. Data shown represent mean ± SD (n=3). ***p* < 0.01. **(D and E)** TEAD2 could regulate the level of ROS in A2780 cells. A2780 cells deal with erastin (10 μM) for 24h and then the intracellular ROS was tested. Data shown represent mean ± SD (n=3). ***p* < 0.01.

that CD4⁺ T cells were obviously involved in the development of OSC.^{37–39} In addition, macrophages and neutrophils were also employed as the potential prognostic markers for OSC.^{40–42} Thus, these studies demonstrated that tumor-infiltrating immune cells could be used as the important indicators for the clinical outcome of OSC patients.

Conclusions

In conclusion, our study analyzed the molecular profiles of *TEAD* family in OSC patients by bioinformatics and experimental strategies. We discovered that TEAD2 was obviously upregulated in OSC. Meanwhile, the higher expression of TEAD2 was significantly associated with poor OS and PFS. Furthermore, the reduced expression of TEAD2 could promote the ferroptosis in OSC. Therefore, our findings suggested a promising insight into *TEAD* family in the OSC population, and provided a personalized prediction tool for prognosis and immune responses. Moreover, TEAD2 had the potential to be the biomarker of diagnosis and prognosis in OSC.

Data Sharing Statement

All data generated or analyzed during this study are included in the manuscript and [Supplementary Materials](#).

Ethics Approval and Informed Consent

According to the National Health and Family Planning Commission Order (No. 11), the human body materials in this study do not need the informed consent statement. The ethics of our study has been approved by the Ethics Committee of Xiangya Hospital of Central South University. The ethical approval number is 202110181.

Consent for Publication

All authors have approved the manuscript for submission.

Funding

This study is supported by grants from the China Postdoctoral Science Foundation (2021T140754, 2020M672521), the National Natural Science Foundation of China (81803035), the Natural Science Foundation of Hunan Province (2020JJ5934, 2019JJ50932), and the Postdoctoral Science Foundation of Central South University (248485).

Disclosure

The authors declare no conflicts of interest for this work.

References

- Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. *CA Cancer J Clin.* 2019;69(4):280–304.
- Bai J, Xie Z, Sun L. Case report: metachronous quadruple cancers including breast cancer and triple genital cancer. *Int J Gen Med.* 2020;13:1575–1580. doi:10.2147/IJGM.S278219
- Hidayat YM, Munizar HAB, Winarno GNA, Hasanuddin SS. Chemokine ligand 5 to predict optimal cytoreduction in ovarian cancer. *Int J Gen Med.* 2020;13:1201–1206. doi:10.2147/IJGM.S280858
- Nesic K, Kondrashova O, Hurley RM, et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. *Cancer Res.* 2021;81:4709–4722. doi:10.1158/0008-5472.CAN-21-0774
- Wan X, Zhang H, Zhang Y, Peng Y. Metastases to the breast from extramammary nonhematological malignancies: case series. *Int J Gen Med.* 2020;13:1105–1114. doi:10.2147/IJGM.S276602
- Li FL, Guan KL. The two sides of Hippo pathway in cancer. *Semin Cancer Biol.* 2021. doi:10.1016/j.semcancer.2021.07.006
- Liu Y, Zhang Q, Wu J, et al. Long non-coding RNA A2M-AS1 promotes breast cancer progression by sponging microRNA-146b to upregulate MUC19. *Int J Gen Med.* 2020;13:1305–1316. doi:10.2147/IJGM.S278564
- Xue C, Liu X, Wen B, et al. Zebrafish vestigial like family member 4b is required for valvulogenesis through sequestration of transcription factor myocyte enhancer factor 2c. *Front Cell Develop Biol.* 2019;7:277. doi:10.3389/fcell.2019.00277
- Yamaguchi N. Multiple roles of vestigial-like family members in tumor development. *Front Oncol.* 2020;10:1266. doi:10.3389/fonc.2020.01266
- He Z, Li R, Jiang H. Mutations and copy number abnormalities of hippo pathway components in human cancers. *Front Cell Develop Biol.* 2021;9:661718. doi:10.3389/fcell.2021.661718
- Qu L, Wu Z, Li Y, et al. A feed-forward loop between IncARSR and YAP activity promotes expansion of renal tumour-initiating cells. *Nat Commun.* 2016;7:12692. doi:10.1038/ncomms12692
- Kalayci M, Hassan IA, Keinan IA, et al. The effect of hemodialysis on axial length, ocular surface, and intraocular pressure in patients with end-stage renal failure. *Int J Gen Med.* 2020;13:1035–1042. doi:10.2147/IJGM.S281546
- Wang X, Wang S, Pang YP, et al. Contrast-enhanced ultrasound assessment of renal parenchymal perfusion in patients with atherosclerotic renal artery stenosis to predict renal function improvement after revascularization. *Int J Gen Med.* 2020;13:1713–1721. doi:10.2147/IJGM.S293316
- Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
- Tang Z, Li C, Zhang K, Yang M, Hu X. GE-mini: a mobile APP for large-scale gene expression visualization. *Bioinformatics.* 2017;33(6):941–943.
- Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. *Neoplasia.* 2004;6(1):1–6. doi:10.1016/S1476-5586(04)80047-2
- Gyorffy B, Gyorffy A, Tulassay Z. [The problem of multiple testing and solutions for genome-wide studies]. *Orv Hetil.* 2005;146(12):559–563. Danish.
- Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
- Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.* 2017;45(D1):D362–D368. doi:10.1093/nar/gkw937
- Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res.* 2017;45(W1):W130–W137. doi:10.1093/nar/gkx356
- Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res.* 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
- Currey L, Thor S, Piper M. TEAD family transcription factors in development and disease. *Development.* 2021;148(12). doi:10.1242/dev.196675
- Brundy S, Mitchell B, Bou-Zgheib N, Santanam N. Endometriosis and ovarian cancer risk, an epigenetic connection. *Ann Transl Med.* 2020;8(24):1715. doi:10.21037/atm-20-2449
- Sun Z, Zhang Q, Yuan W, et al. MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis. *J Exp Clin Cancer Res.* 2020;39(1):250. doi:10.1186/s13046-020-01705-9
- Demircan NC, Boussios S, Tasci T, Ozturk MA. Current and future immunotherapy approaches in ovarian cancer. *Ann Transl Med.* 2020;8(24):1714. doi:10.21037/atm-20-4499
- Joo JS, Cho SY, Rou WS, et al. TEAD2 as a novel prognostic factor for hepatocellular carcinoma. *Oncol Rep.* 2020;43(6):1785–1796.
- Samartzis EP, Labidi-Galy SI, Moschetta M, et al. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review. *Ann Transl Med.* 2020;8(24):1712. doi:10.21037/atm-20-3022a
- Liu J, Zhao X, Wang K, et al. A novel YAP1/SLC35B4 regulatory axis contributes to proliferation and progression of gastric carcinoma. *Cell Death Dis.* 2019;10(6):452. doi:10.1038/s41419-019-1674-2
- Tang R, Hua J, Xu J, et al. The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. *Ann Transl Med.* 2020;8(21):1347. doi:10.21037/atm-20-2554a
- Yu T, Song J, Zhou H, et al. Nuclear TEAD4 with SIX1 overexpression is an independent prognostic marker in the stage I-III colorectal cancer. *Cancer Manag Res.* 2021;13:1581–1589. doi:10.2147/CMAR.S260790
- Valpione S, Mundra PA, Galvani E, et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. *Nat Commun.* 2021;12(1):4098. doi:10.1038/s41467-021-24343-x
- Brase JC, Walter RFH, Savchenko A, et al. Role of tumor-infiltrating B cells in clinical outcome of patients with melanoma treated with dabrafenib plus trametinib. *Clin Cancer Res.* 2021;27:4500–4510. doi:10.1158/1078-0432.CCR-20-3586
- Mhaidly R, Mechta-Grigoriou F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. *Immunol Rev.* 2021;302(1):259–272. doi:10.1111/imr.12978
- Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. *Semin Cancer Biol.* 2020. doi:10.1016/j.semcancer.2020.08.017
- Fucikova J, Rakova J, Hensler M, et al. TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. *Clin Cancer Res.* 2019;25(15):4820–4831. doi:10.1158/1078-0432.CCR-18-4175
- Mesnage SJL, Auguste A, Genestie C, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). *Ann Oncol.* 2017;28(3):651–657. doi:10.1093/annonc/mdw625

37. Laumont CM, Wouters MCA, Smazynski J, et al. Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer. *Clin Cancer Res.* 2021;27(14):4089–4100. doi:10.1158/1078-0432.CCR-20-4394
38. Xu R, Wu M, Liu S, et al. Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4(+) Treg cells in ovarian cancer cells microenvironment. *Cell Death Dis.* 2021;12(1):22. doi:10.1038/s41419-020-03272-5
39. Wei J, Xie Q, Liu X, et al. Identification the prognostic value of glutathione peroxidases expression levels in acute myeloid leukemia. *Ann Transl Med.* 2020;8(11):678. doi:10.21037/atm-20-3296
40. Liu QF, Feng ZY, Jiang LL, Xu TT, Li SM, Liu KR. Immune cell infiltration as signatures for the diagnosis and prognosis of malignant gynecological tumors. *Front Cell Develop Biol.* 2021;9:702451. doi:10.3389/fcell.2021.702451
41. Liu R, Hu R, Zeng Y, Zhang W, Zhou HH. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: a gene expression-based computational study. *EBioMedicine.* 2020;51:102602. doi:10.1016/j.ebiom.2019.102602
42. Wei R, Qiu H, Xu J, et al. Expression and prognostic potential of GPX1 in human cancers based on data mining. *Ann Transl Med.* 2020;8(4):124. doi:10.21037/atm.2020.02.36

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>